IP Library Granted Patent US 11,913,950
Granted Patent B2
US 11,913,950 · App. 16/195,582 · Granted Feb 27, 2024

Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis

Inventor: Anthony Marotta (Burnaby, CA)
G01N33/564C07K14/47C07K14/4713G01N33/54306G01N33/6893G01N2440/18G01N2800/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,913,950
App. No.
16/195,582
Granted
Feb 27, 2024
Kind
B2
Abstract

The present invention provides citrullinated 14-3-3η peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.

Claims (12)

1. A autoantibodies against a citrullinated 14-3-3 protein or fragment thereof in a subject comprising

i) obtaining a biological sample from a subject suspected of having or at risk for developing rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, and psoriatic arthritis;

ii) contacting said biological sample from said subject with at least one citrullinated 14-3-3 protein or fragment thereof under a condition suitable for the formation of at least one immune complex between the citrullinated 14-3-3 protein or fragment thereof and autoantibodies against the citrullinated 14-3-3 protein or fragment thereof that may be present in the biological sample; and

iii) detecting the presence of immune complexes between the citrullinated 14-3-3 protein or fragment thereof and autoantibodies against the citrullinated 14-3-3 protein or fragment thereof;

wherein the citrullinated 14-3-3 protein or fragment thereof comprises a citrulline residue at a position selected from the group consisting of position 4, position 12, position 19, position 42, position 61, position 86 and position 227 of SEQ ID NO: 5; or comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-22.

2. The method of claim 1 , wherein said detecting step further comprises measuring the amount of autoantibodies against the citrullinated 14-3-3 protein or fragment thereof.

3. The method of claim 1 , wherein the citrullinated 14-3-3 protein is citrullinated 14-3-3 eta.

4. The method of claim 1 , wherein the citrullinated 14-3-3 protein is a fragment of citrullinated 14-3-3 eta.

5. The method according to claim 1 , wherein the citrullinated 14-3-3 protein or fragment thereof is detectably labeled with a label selected from the group consisting of a radioactive label, a luminescent label, and a fluorescent label, and an enzyme.

6. The method according to claim 1 , wherein the citrullinated 14-3-3 protein or fragment thereof is bound to a solid support.

7. The method according to claim 2 , wherein the autoantibodies are detected by an ELISA assay.

8. The method according to claim 1 , wherein said detection occurs by chemiluminesence.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2021
From: MAROTTA, ANTHONY
To: AUGUREX LIFE SCIENCES CORP.
Reel/Frame 058447/0303 →
Continuity (3)
Continuation 14353281
Provisional Application 61550046 · Oct 21, 2011
Related Publication 20190310249A1 · Oct 10, 2019